Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($0.04), $0.57 better than the analyst estimate of ($0.61). Revenue for the quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Earnings Management Comments

REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMDAugust 7, 2019 4:05 PM